Cellectis to license recently-granted CRISPR patents – Life Sciences Intellectual Property Review
Life Sciences Intellectual Property Review |
Cellectis to license recently-granted CRISPR patents
Life Sciences Intellectual Property Review Both patents centre on the use of CRISPR technology in T cells and “claim methods by which T cells are gene edited using transient expression of CRISPR/Cas9 components”, according to the release. Last year, Cellectis was granted European patent number … Rupert Beale America May Fall Behind in Genetic Technologies, and That's OK |
